BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 22820988)

  • 1. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
    Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
    Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
    Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the structure and function of the pseudokinase domain in JAK2.
    Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
    Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
    Ungureanu D; Wu J; Pekkala T; Niranjan Y; Young C; Jensen ON; Xu CF; Neubert TA; Skoda RC; Hubbard SR; Silvennoinen O
    Nat Struct Mol Biol; 2011 Aug; 18(9):971-6. PubMed ID: 21841788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
    Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
    PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
    Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
    Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.
    Sanz A; Ungureanu D; Pekkala T; Ruijtenbeek R; Touw IP; Hilhorst R; Silvennoinen O
    PLoS One; 2011 Apr; 6(4):e18522. PubMed ID: 21533163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
    Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
    Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.
    Virtanen AT; Haikarainen T; Sampathkumar P; Palmroth M; Liukkonen S; Liu J; Nekhotiaeva N; Hubbard SR; Silvennoinen O
    Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.
    Liosi ME; Krimmer SG; Newton AS; Dawson TK; Puleo DE; Cutrona KJ; Suzuki Y; Schlessinger J; Jorgensen WL
    J Med Chem; 2020 May; 63(10):5324-5340. PubMed ID: 32329617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain.
    McNally R; Li Q; Li K; Dekker C; Vangrevelinghe E; Jones M; Chène P; Machauer R; Radimerski T; Eck MJ
    ACS Chem Biol; 2019 Apr; 14(4):587-593. PubMed ID: 30763067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.
    Liosi ME; Ippolito JA; Henry SP; Krimmer SG; Newton AS; Cutrona KJ; Olivarez RA; Mohanty J; Schlessinger J; Jorgensen WL
    J Med Chem; 2022 Jun; 65(12):8380-8400. PubMed ID: 35653642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.
    Wan S; Coveney PV
    J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
    Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
    Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.
    Henry SP; Liosi ME; Ippolito JA; Cutrona KJ; Krimmer SG; Newton AS; Schlessinger J; Jorgensen WL
    ACS Med Chem Lett; 2022 May; 13(5):819-826. PubMed ID: 35586418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells.
    Wu QY; Ma MM; Tong YX; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
    Int J Biol Macromol; 2018 Oct; 117():271-279. PubMed ID: 29842959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.
    Shan Y; Gnanasambandan K; Ungureanu D; Kim ET; Hammarén H; Yamashita K; Silvennoinen O; Shaw DE; Hubbard SR
    Nat Struct Mol Biol; 2014 Jul; 21(7):579-84. PubMed ID: 24918548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.